Page 1082 - Clinical Immunology_ Principles and Practice ( PDFDrive )

ChaPTEr 77 Immunotherapy of Cancer 1047

First results from the phase I/II CheckMate 032 study. Presented at: 2016 57. Rooney C, Leen A. Moving successful virus-specific T-cell therapy for
SITC Annual Meeting; November 9-13, 2016; National Harbor, MD. hematopoietic stem cell recipients to late phase clinical trials. Mol Ther
36. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients Nucleic Acids 2012;1(11):e55.
with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a 58. Rooney CM, Leen AM, Vera JF, et al. T lymphocytes targeting native
multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17(6): receptors. Immunol Rev 2014;257(1):39–55.
717–26. 59. Kohler G, Milstein C. Continuous cultures of fused cells secreting
37. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent antibody of predefined specificity. Nature 1975;256(5517):495–7.
squamous-cell carcinoma of the head and neck. N Engl J Med 60. Glassman PM, Balthasar JP. Mechanistic considerations for the use of
2016;375(19):1856–67. monoclonal antibodies for cancer therapy. Cancer Biol Med
38. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with 2014;11(1):20–33.
nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 61. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody
2015;372:311–19. market. MAbs 2015;7(1):9–14.
39. Sharma A, Blando J, Allison JP, et al. Evaluation of immune infiltrates 62. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of
and inhibitory immune checkpoints in human pancreatic tumors yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus
compared to other tumors. Manuscript in review. rituximab immunotherapy for patients with relapsed or refractory
40. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.
Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic J Clin Oncol 2002;20(10):2453–63.
adenocarcinoma. J Immunother 2010;33(8):828–33. 63. Report SGaM. Positive Data from Pivotal Trial of Brentuximab Vedotin
41. Kawalec P, Paszulewicz A, Holko P, et al. Sipuleucel-T immunotherapy (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at 2010
for castration-resistant prostate cancer. A systematic review and Annual Meeting of the American Society of Hematology (ASH)
meta-analysis. Arch Med Sci 2012;8(5):767–75. (Corporate Press Release).
42. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in 64. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of
combination with radiotherapy in metastatic castration-resistant blinatumomab for adult patients with relapsed or refractory B-precursor
prostate cancer: results from an open-label, multicenter phase I/II study. acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Ann Oncol 2013;24(7):1813–21. Lancet Oncol 2015;16(1):57–66.
43. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after 65. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy.
radiotherapy in patients with metastatic castration-resistant prostate Nat Rev Cancer 2004;4(1):11–22.
cancer that had progressed after docetaxel chemotherapy (CA184-043): 66. Todd Michael Bauer KPP, Karen A. Autio, Patrick Alexander Ott,
a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol Melinda Whiteside, Martin Oft, Jeffrey R. Infante, F. Stephen Hodi, Jedd
2014;15(7):700v12. D. Wolchok. A first-in-human study of pegylated recombinant human
44. Watts TH. TNF/TNFR family members in costimulation of T cell IL-10 (AM0010), daily administered for four months in selected
responses. Ann Rev Immunol 2005;23:23–68. advanced solid tumors. J Clin Oncol 2014;32(Suppl.; abstract
45. Liakou CI, Kamat A, Tang DN, et al. CTLA-4 blockade increases TPS3126).
IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to 67. Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the
regulatory T cells in cancer patients. Proc Natl Acad Sci USA future. Oncoimmunology 2013;2(3):e23403.
2008;105(39):14987–92. 68. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of
46. Ng Tang D, Shen Y, Sun J, et al. Increased frequency of ICOS+ CD4 T immunotherapy drugs. Nat Rev Drug Discov 2015;14(9):642–62.
cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer 69. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene
Immunol Res 2013;1(4):229–34. Laherparepvec Improves Durable Response Rate in Patients With
47. Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in Advanced Melanoma. J Clin Oncol 2015;33(25):2780–8.
combination with exemestane in patients with advanced breast cancer 70. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin
and treatment-associated modulation of inducible costimulator signalling prevents anti-tumour immunity. Nature
expression on patient T cells. Clin Cancer Res 2010;16(13): 2015;523(7559):231–5.
3485–94. 71. Ascierto PA, Agarwala S, Botti G, et al. Future perspectives in melanoma
48. Fan X, Quezada SA, Sepulveda MA, et al. Engagement of the ICOS research: meeting report from the “Melanoma Bridge.” Napoli,
pathway markedly enhances efficacy of CTLA-4 blockade in cancer December 1st-4th 2015. J Transl Med 2016;14(1):313.
immunotherapy. J Exp Med 2014;211(4):715–25. 72. Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T
49. Weber JP, Fuhrmann F, Feist RK, et al. ICOS maintains the T follicular Cell-mediated immunotherapy. Cancer Discov 2016;6(2):202–16.
helper cell phenotype by down-regulating Kruppel-like factor 2. 73. Murray PJ. The JAK-STAT signaling pathway: input and output
J Exp Med 2015;212(2):217–33. integration. J Immunol 2007;178(5):2623–9.
50. Bartkowiak T, Curran MA. 4-1BB Agonists: multi-potent potentiators of 74. Gao J, Shi LZ, Zhao H, et al. Loss of IFN-gamma pathway genes in
tumor immunity. Front Oncol 2015;5:117. tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell
51. Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent 2016;167(2):397–404.e9.
immune-stimulating target in late-stage cancer patients. Cancer Res 75. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with
2013;73(24):7189–98. acquired resistance to PD-1 blockade in melanoma. N Engl J Med
52. Yee C. The use of endogenous T cells for adoptive transfer. Immunol 2016;375(9):819–29.
Rev 2014;257(1):250–63. 76. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in
53. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized the tumor microenvironment. Nat Immunol 2013;14(10):1014–22.
immunotherapy for human cancer. Science 2015;348(6230):62–8. 77. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and
54. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive acquired resistance to cancer Immunotherapy. Cell 2017;168(4):
T-cell therapy for cancer. Immunol Rev 2014;257(1):56–71. 707–23.
55. Dai H, Wang Y, Lu X, et al. Chimeric antigen receptors modified T-Cells 78. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium
for cancer therapy. J Natl Cancer Inst 2016;108(7). promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
56. Teachey DT, Lacey SF, Shaw PA, et al. Identification of Predictive Science 2015;350(6264):1084–9.
Biomarkers for Cytokine Release Syndrome after Chimeric Antigen 79. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by
Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer CTLA-4 blockade relies on the gut microbiota. Science
Discov 2016;6(6):664–79. 2015;350(6264):1079–84.